Abstract | INTRODUCTION: PATIENTS AND METHODS: Open prospective, quasi-experimental cohort. LEVO was given as compassionate treatment in patients with refractory post-surgical low cardiac output syndrome. Every patient received an IV infusion of LEVO at 6 microg/kg during a fifteen minutes period, followed by a 24 h IV infusion at 0.1 microg/kg/min. Clinical improvement of cardiac output was the primary end point of the study. Two independent observers performed clinical evaluation, bidimensional echocardiogram, hemodynamic and laboratory tests were performed pre and after LEVO infusion. RESULTS: LEVO was infused in 18 opportunities (fourteen children). The response was considered successful in 9/18 interventions (50%; p= 0.004). Both inotropic score (12.1 vs. 6,1, p= 0.01) and A-VDO(2)2 (26.78 +/- 11.5% vs. 20.81 +/- 7.72%, p= 0.029) showed reduction, while SvO2 improved (69.5 +/- 11.4% vs. 76 +/- 9.29%, p= 0.03). No adverse effects were noticed. Four patients died, none of them related to LEVO administration. CONCLUSIONS: LEVO improved cardiac output in 50% of the interventions with post-surgical LCOS and no adverse effect was observed.
|
Authors | Ricardo Magliola, Guillermo Moreno, Juan C Vassallo, Luis M Landry, María Althabe, María Balestrini, Alberto Charroqui, Gladys Salgado, Evangelina Lataza, Anthony C Chang |
Journal | Archivos argentinos de pediatria
(Arch Argent Pediatr)
Vol. 107
Issue 2
Pg. 139-45
(Apr 2009)
ISSN: 1668-3501 [Electronic] Argentina |
Vernacular Title | Levosimendán, un nuevo agente inotrópico: experiencia en niños con fallo cardíaco agudo. |
PMID | 19452086
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Cardiotonic Agents
- Hydrazones
- Pyridazines
- Simendan
|
Topics |
- Acute Disease
- Adolescent
- Cardiac Output, Low
(drug therapy)
- Cardiotonic Agents
(therapeutic use)
- Child
- Child, Preschool
- Female
- Humans
- Hydrazones
(therapeutic use)
- Infant
- Male
- Prospective Studies
- Pyridazines
(therapeutic use)
- Simendan
|